(Q43917196)

English

Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial

scientific article published in March 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial (English)

1 reference

Europe PubMed Central

28 November 2017

0 references

1 reference

based on heuristic

inferred from title

hypertriglyceridemia

1 reference

based on heuristic

inferred from title

insulin resistance

1 reference

based on heuristic

inferred from title

systemic inflammation

1 reference

based on heuristic

inferred from title

Rudi Westendorp

3

object named as

Rudi G Westendorp

1 reference

Europe PubMed Central

28 November 2017

author name string

Iris J Jonkers

1

1 reference

Europe PubMed Central

28 November 2017

Martina F Mohrschladt

2

1 reference

Europe PubMed Central

28 November 2017

Arnoud van der Laarse

4

1 reference

Europe PubMed Central

28 November 2017

Augustinus H Smelt

5

1 reference

Europe PubMed Central

28 November 2017

language of work or name

0 references

publication date

1 March 2002

1 reference

Europe PubMed Central

28 November 2017

American Journal of Medicine

1 reference

Europe PubMed Central

28 November 2017

112

1 reference

Europe PubMed Central

28 November 2017

4

1 reference

Europe PubMed Central

28 November 2017

275-280

1 reference

Europe PubMed Central

28 November 2017

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Hypertriglyceridemia as a cardiovascular risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Hypertriglyceridaemia and hypercoagulability

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Tr

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

The PPARalpha-leukotriene B4 pathway to inflammation control.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

[Rapid physiological coagulation method in determination of fibrinogen]

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Determination of tumour necrosis factor-alpha and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

In vivo protection against endotoxin by plasma high density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

HDL, its enzymes and its potential to influence lipid peroxidation.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Changes of lipolytic enzymes cluster with insulin resistance syndrome. Botnia Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Altering Triglyceride Concentrations Changes Insulin-Glucose Relationships in Hypertriglyceridemic Patients: Double-Blind Study With Gemfibrozil With Implications for Atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Inhibition of proinflammatory cytokine production by pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in pri

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901123-8

7 January 2021

Identifiers

10.1016/S0002-9343(01)01123-8

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43917196&oldid=2104377369"